TY - JOUR
T1 - Atrial Natriuretic Peptide in the high normal range is associated with lower prevalence of insulin resistance
AU - Jujić, Amra
AU - Nilsson, Peter M
AU - Persson, Margaretha
AU - Holst, Jens Juul
AU - Torekov, Signe Sørensen
AU - Lyssenko, Valeriya
AU - Groop, Leif
AU - Melander, Olle
AU - Magnusson, Martin
PY - 2016/4
Y1 - 2016/4
N2 - Context: We have previously shown that high levels of atrial natriuretic peptides (ANPs) are associated with decreased risk of future diabetes development; however, the mechanism behind this relationship is not fully understood. Objective: In this study, we prospectively analyzed whether baseline plasma levels of midregional proANP (MR-proANP) are associated with insulin resistance and postchallenge incretin secretion after long-term follow-up. Design/Setting/Patients: MR-proANP was measured in 2243 nondiabetic individuals at baseline examination of the Malmö Diet and Cancer Cardiovascular cohort. At reexamination 16.5 years later, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1, insulin, glucose, and glucagon were measured during an oral glucose tolerance test. Results: Linear regression analyses showed that each 1 SD increment of baseline MR-proANP levels was inversely associated with insulin resistance calculated as homeostasis model assessment of insulin resistance (per 1 SD change, β = -.066, P = .001) at follow-up. A logistic regression analysis showed that each 1 SD increment of baseline ANP levels resulted in lower risk of belonging to the upper quartile of homeostasis model assessment of insulin resistance at follow-up (odds ratio 0.88, 95% confidence interval 0.78-0.99, P = .043). In linear regression analyses, each 1 SD increment in baseline MR-proANP levels was associated with greater GIP release (per 1 SD change, β = .055; P = .020) 120 minutes after 75 g glucose intake but not with glucagon-like peptide-1 release (per 1 SD change, β = .016, P = .493) 120 minutes after 75 g glucose intake at 16.5 years of follow-up. Conclusion: Midlife exposure to ANP within the high normal range is associated with a lower risk of insulin resistance. Furthermore, midlife exposure to ANP within the high normal range is associated with a greater postchallenge GIP secretion at follow-up, possibly explaining the lower prevalence of insulin resistance.
AB - Context: We have previously shown that high levels of atrial natriuretic peptides (ANPs) are associated with decreased risk of future diabetes development; however, the mechanism behind this relationship is not fully understood. Objective: In this study, we prospectively analyzed whether baseline plasma levels of midregional proANP (MR-proANP) are associated with insulin resistance and postchallenge incretin secretion after long-term follow-up. Design/Setting/Patients: MR-proANP was measured in 2243 nondiabetic individuals at baseline examination of the Malmö Diet and Cancer Cardiovascular cohort. At reexamination 16.5 years later, glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1, insulin, glucose, and glucagon were measured during an oral glucose tolerance test. Results: Linear regression analyses showed that each 1 SD increment of baseline MR-proANP levels was inversely associated with insulin resistance calculated as homeostasis model assessment of insulin resistance (per 1 SD change, β = -.066, P = .001) at follow-up. A logistic regression analysis showed that each 1 SD increment of baseline ANP levels resulted in lower risk of belonging to the upper quartile of homeostasis model assessment of insulin resistance at follow-up (odds ratio 0.88, 95% confidence interval 0.78-0.99, P = .043). In linear regression analyses, each 1 SD increment in baseline MR-proANP levels was associated with greater GIP release (per 1 SD change, β = .055; P = .020) 120 minutes after 75 g glucose intake but not with glucagon-like peptide-1 release (per 1 SD change, β = .016, P = .493) 120 minutes after 75 g glucose intake at 16.5 years of follow-up. Conclusion: Midlife exposure to ANP within the high normal range is associated with a lower risk of insulin resistance. Furthermore, midlife exposure to ANP within the high normal range is associated with a greater postchallenge GIP secretion at follow-up, possibly explaining the lower prevalence of insulin resistance.
U2 - 10.1210/jc.2015-3518
DO - 10.1210/jc.2015-3518
M3 - Journal article
C2 - 26815880
SN - 0021-972X
VL - 101
SP - 1372
EP - 1380
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 4
ER -
